Prestige Consumer Healthcare Inc.

Prestige Consumer Healthcare Inc.

NNYSE:PBH
48.00
USD
+1.81
(+3.92%)
3.25EPS
14.07P/E
2.17BMarket Cap
Feb 04Next Earn
Prestige Consumer Healthcare Inc.
NYSE:PBH
(New York Stock Exchange)

Recent

price

48.00

P/E

ratio

14.07

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
USD
6.72
8.77
12.25
11.57
13.7
15.28
16.65
19.61
18.74
18.99
18.79
21.62
22.6
22.62
22.89
22.47
24.54
Revenue per Share
0.58
0.74
1.29
1.41
1.5
1.89
1.31
6.4
-0.69
2.81
3.28
4.09
-1.65
4.21
4.32
3.93
3.26
Basic EPS, GAAP
1.72
1.33
2.51
2.11
2.88
3.27
2.75
3.72
3.43
3.94
4.25
4.98
4.45
4.81
4.9
5.09
4.5
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
7.22
8
9.34
10.87
12
14.11
15.53
22.22
21.16
23.38
27.21
31.38
29.12
33.22
37.06
39.89
41.05
Book Value per Share
-11.56
-23.3
-20.79
-19.73
-34.38
-36.74
-50.92
-41.9
-38.42
-37.61
-33.97
-33.77
-28.62
-23.95
-19.95
-20.99
-44.7
Tangible Book Value per Share
50
50
51
52
52
53
53
53
52
51
50
50
50
50
50
48
48
Basic Weighted Avg Shares
337
441
620
597
715
806
882
1,041
976
963
943
1,087
1,128
1,125
1,138
1,089
1,167
Sales/Revenue/Turnover
22.63
23.31
30.94
31.57
29.04
32.29
29.19
30.29
6.79
30.23
31.78
30.45
30.84
30.43
30.7
28.42
24.95
Operating Margin (%)
10
11
13
13
18
24
26
33
32
29
30
32
33
31
30
31
37
Depreciation Expense
29
37
66
73
78
100
69
340
-36
142
165
205
-82
209
215
190
155
Net Income, GAAP
39.87
39.15
38.22
28.63
38.6
36.44
37.4
- -
- -
25.57
19.32
21.75
- -
24.16
24.49
26.1
27.04
Effective Tax Rate (%)
8.68
8.44
10.56
12.16
10.95
12.39
7.87
32.61
-3.67
14.77
17.46
18.9
-7.3
18.6
18.86
17.48
13.29
Profit Margin (%)
53
83
68
93
103
142
172
180
174
216
148
150
231
258
342
311
324
Working Capital
487
1,124
971
934
1,561
1,625
2,194
1,993
1,799
1,760
1,506
1,497
1,357
1,134
1,036
1,033
2,113
LT Debt
362
403
478
563
628
744
823
1,179
1,096
1,171
1,358
1,578
1,447
1,655
1,835
1,888
1,945
Total Equity
6.1
5.28
8
9.18
6.94
7.27
4.77
- -
- -
7.47
8.3
8.71
- -
9.24
8.96
7.87
6.16
Return on Invested Capital (%)
6.08
5.25
7.91
8.25
6.95
6.76
4.75
- -
- -
7.34
7.95
8.58
- -
9.28
8.83
7.63
5.86
Return on Capital (%)
8.46
9.74
14.89
13.95
13.14
14.56
8.86
33.94
-3.15
12.55
13.02
13.99
-5.44
13.5
12.3
10.22
8.23
Return on Common Equity (%)

Capital Structure

USD

•

in mil. unless spec.
Mar'26
Jun'27
Sep'27
ST Debt
13
24
14
LT Borrowings
994
2,007
2,079
LT Finance Leases
39
36
34
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
47
47
47
Market Capitalization
2,805
2,239
2,173

Working Capital

USD

•

in mil. unless spec.
Mar'26
Jun'27
Sep'27
Total Current Assets
431
497
492
Cash, Cash Equivalents & STI
64
89
47
Accounts Receivable, Net
209
187
244
Inventories
159
190
179
Total Current Liabilities
121
154
169
Payables & Accruals
96
122
144
ST Debt
13
24
14
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
10.56%
7.2%
2.87%
Free Cash Flow
4.58%
3.35%
1.3%
Net Income, GAAP
-71.19%
-95.7%
-11.32%
Sales/Revenue/Turnover
3.34%
3.11%
-4.31%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
267
284
290
297
1,138
2026
250
274
283
282
1,089
2027
266
336
- -
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
0.98
1.1
1.23
1.01
4.32
2026
0.96
0.86
0.98
1.14
3.93
2027
0.61
0.53
- -
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -
Business
Prestige Consumer Healthcare Inc. (NYSE: PBH) develops, manufactures, markets, distributes, and sells over-the-counter (OTC) healthcare products and select household cleaning items to retailers across North America and select international markets; its portfolio spans digestive care including Beano, Phazyme, Tagamet, Fleet, and Bacid; eye, ear, nose, and throat remedies such as Clear Eyes, Chloraseptic, Luden's throat lozenges, Debrox, NasalCrom, and Murine; pain relief options like BC Powder and Goody's Headache Powder; oral care products including Efferdent and DenTek; pediatric care with PediaCare, Little Remedies, Boudreaux's Butt Paste, and Nix lice treatments; skin care featuring Compound W wart removal; sleep aids; women's health comprising Monistat yeast infection treatments and Summer's Eve feminine hygiene; and household cleaners such as Spic and Span and Comet. Founded in 1996 through the merger of Medtech Products, Prestige Brands International, and Spic and Span, the company is headquartered in Tarrytown, New York, with a manufacturing facility in Lynchburg, Virginia, and additional operations in the United States, Canada, Australia, and other regions. In fiscal 2026, Prestige entered a definitive agreement to acquire Pillar5 Pharma Inc., a sterile ophthalmic manufacturer and key supplier for Clear Eyes, from Anjac SAS for approximately $150 million in a cash-funded deal expected to close in the third fiscal quarter, enhancing vertical integration, securing 90% in-house manufacturing for eye care and related products, and enabling expansion into OTC men's health via Anjac's men's grooming capabilities including hair loss, skin care, and stress management innovations; the transaction remains roughly EPS-neutral while bolstering supply chain resilience amid robust Clear Eyes demand.

Company News

  • What Premium Brands (PBH) Said on Its Q3 Earnings Call

  • Prestige Consumer Healthcare Q2 Earnings Call Highlights

  • Prestige Consumer Healthcare Inc. (PBH) Q2 2027 Earnings Call Transcript

  • Compared to Estimates, Prestige Consumer Healthcare (PBH) Q2 Earnings: A Look at Key Metrics

  • Prestige Consumer Healthcare Inc. Reports Fiscal 2027 Second Quarter Results

  • Amylyx Pharmaceuticals to Host Investor Event at ObesityWeek® 2026 Featuring Leading PBH Experts

  • Riverwater Small Cap Strategy Q3 2026 Portfolio Update

  • Prestige Consumer Healthcare Inc (PBH) Shares Fall 3.4% -- What GF Score of 70 Tells Investors

  • Is it Apt to Retain Prestige Consumer Stock in Your Portfolio Now?

  • Prestige Consumer Healthcare to Release Fiscal 2027 Second Quarter Earnings Results

  • Amylyx's Avexitide Phase III Win Sets Up FDA Filing for PBH Treatment

  • Best Value Stocks to Buy for October 1st

  • PBH vs. NEOG: Which Stock Is the Better Value Option?

  • More Than Half of U.S. Women Have Avoided Talking About an Intimate Wellness Concern Because They Felt Embarrassed or Uncomfortable, New Summer's Eve® Survey Finds

  • Premium Brands (TSE:PBH) Reaches New 52-Week Low – Here’s What Happened

  • PBH or NEOG: Which Is the Better Value Stock Right Now?

  • Prestige Consumer Healthcare Inc. (PBH) Presents at Barclays 19th Annual Global Consumer Staples Conference Transcript

  • Prestige Consumer Healthcare Inc. to Participate in Barclays Global Consumer Conference

  • Football Stress May Be Following Fans to Bed, According to the Inaugural DenTek® Football Stress Test

  • PBH vs. SYK: Which Stock Is the Better Value Option?